LUNG
Pulmonx Corporation (LUNG) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue base remains small at an EV/Sales of 1.10, leaving room for growth if execution improves.
No material change this month.
Profitability
TTM margins remain deeply negative, with EBIT margin at -50.0% and net margin at -55.0%.
Return metrics are still severely negative, including ROIC at -48.4% and ROE at -96.7%.
Financial Strength
Liquidity remains solid with a current ratio of 4.32 and cash ratio of 2.74.
Balance sheet leverage is manageable, with debt-to-equity at 1.43 and net debt to EBITDA near flat at -0.01.
Cash Generation
Operating cash flow and free cash flow remain negative, with FCF yield at -31.8% and OCF yield at -32.1%.
Cash conversion remains weak despite low capex intensity, as operating cash flow is still negative.
Capital Efficiency
Asset efficiency is mixed, with asset turnover at 0.76 and fixed asset turnover at 4.57.
Working capital remains tied up, with a cash conversion cycle of 264 days and inventory days near 298.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Pulmonx Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

